OVID (Ovid Therapeutics) 10-Year Sharpe Ratio: N/A (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OVID Ovid Therapeutics Inc OVID
34 GF Score
Price $2.71
GF Value $0.84
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ovid Therapeutics 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-09-21), Ovid Therapeutics's 10-Year Sharpe Ratio is Not available.

Ovid Therapeutics  (NAS:OVID) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Ovid Therapeutics 10-Year Sharpe Ratio Related Terms

OVID vs ZURA, ARTV, SCTX: 10-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Ovid Therapeutics's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovid Therapeutics 10-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's 10-Year Sharpe Ratio falls into.


OVID
34GF Score
Ovid Therapeutics Inc OVID
10-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ovid Therapeutics 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued. The current stock price of $2.71 is trading 222.6% above its estimated GF Value™ of $0.84. GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.

Key valuation signals for OVID:

  • 10-Year Sharpe Ratio: N/A
  • GF Value™: $0.84 vs. price of $2.71 (222.6% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score

Get the complete analysis for OVID

10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.71
Price
$0.84
GF Value